naslacrimal duct probing
Procedurenasolacrimal duct probing
NCT Number: NCT07593469
This study aims to provide evidence on the optimal timing and efficacy of lacrimal probing in infants with congenital NLDO to minimize morbidity and healthcare costs .
Trial opening soon.
Get Notified1 day–12 month
All sexes
Interventional
Not applicable
Congenital nasolacrimal duct obstruction (CNLDO) manifests with symptoms such as excessive tearing, lash crusting, and mucopurulent secretions. A significant cohort study revealed that CNLDO affects one in nine newborns, highighting its public health significance 1.
Controversies per-sist regarding the most appropriate time and type of intervention for managing CNLDO2 .
Standard early management typically includes hydrostatic lacrimal sac massage combined with topical antibiotics. Many ophthalmologists believe that a majority of obstructions resolve spontaneously with massage; however, around 25% of children may require additional intervention such as probing 3.
Currently, there is no established consensus on the optimal timing for intervention in theses cases. Because of the possibility of spontaneous resolution, some authors recommend postponing probing until after one year of age . Conversely, other studies suggest that delaying probing beyond six months may increase the risk of inflammation and fibrosis, potentially lowering the success rates of later interventions 4.
Aim of the study This study aims to provide evidence on the optimal timing and efficacy of lacrimal probing in infants with congenital NLDO to minimize morbidity and healthcare costs .
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
nasolacrimal duct probing
Time frame: 3 months
Munk Scale, which ranges from 0 (no tearing) to 5 (constant tearing) based on daily wiping frequency.
TEARS Scale, which measures four subscales: Times of wiping, Effects (clinical), Activity limitations, and Reflex tearing.
Contact information is provided by the study sponsor or research team.
Hany Mahmoud,MD
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06428266
Eye Diseases, Lacrimal Apparatus Diseases
Mexico City, Mexico
View Trial DetailsNCT05999058
Eye Diseases, Lacrimal Apparatus Diseases
Tianjin, Tianjin Municipality, China
View Trial DetailsNCT03960996
Eye Diseases, Lacrimal Apparatus Diseases
Ostrava, Moravian-Silesian Region, Czechia
View Trial DetailsNCT03411889
Eye Diseases, Lacrimal Apparatus Diseases
Brighton, East Sussex, United Kingdom
View Trial Details